Daivobet 50 mikrog/ g / 0.5 mg/ g নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

daivobet 50 mikrog/ g / 0.5 mg/ g

leo pharma (2) - kalsipotriolmonohydrat / betametasondipropionat - gel - 50 mikrog/ g / 0.5 mg/ g

Daivobet 50 mikrog/ g / 0.5 mg/ g নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

daivobet 50 mikrog/ g / 0.5 mg/ g

leo pharma (2) - kalsipotriolmonohydrat / betametasondipropionat - salve - 50 mikrog/ g / 0.5 mg/ g

Enstilar 50 mikrog/ g / 0.5 mg/ g নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

enstilar 50 mikrog/ g / 0.5 mg/ g

leo pharma (2) - kalsipotriolmonohydrat / betametasondipropionat - skum - 50 mikrog/ g / 0.5 mg/ g

Calcipotriol/Betamethasone Sandoz 50 mikrog/ g / 0.5 mg/ g নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

calcipotriol/betamethasone sandoz 50 mikrog/ g / 0.5 mg/ g

sandoz - københavn - kalsipotriolmonohydrat / betametasondipropionat - salve - 50 mikrog/ g / 0.5 mg/ g

Calcipotriol/Betamethasone Aristo 50 mikrog/ g / 0.5 mg/ g নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

calcipotriol/betamethasone aristo 50 mikrog/ g / 0.5 mg/ g

aristo pharma gmbh - kalsipotriolmonohydrat / betametasondipropionat - gel - 50 mikrog/ g / 0.5 mg/ g

Calcipotriol/Betamethasone Orifarm 50 mikrog/ g / 0.5 mg/ g নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

calcipotriol/betamethasone orifarm 50 mikrog/ g / 0.5 mg/ g

orifarm generics a/s - kalsipotriolmonohydrat / betametasondipropionat - gel - 50 mikrog/ g / 0.5 mg/ g

Pravafenix ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

pravafenix

laboratoires smb s.a. - fenofibrate, pravastatin - dyslipidemiene - lipid modifiserende midler - pravafenix er indisert for behandling av høy-koronar-hjerte-sykdommer (chd)-risiko voksne pasienter med blandet dyslipidaemia høye triglyserider og lave hdl-cholesterol (c) nivåer hvis ldl-c nivåer er tilstrekkelig kontrollert mens på en behandling med pravastatin-40-mg monoterapi.

Tepadina ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

tepadina

adienne s.r.l. s.u. - tiotepa - hematopoietisk stamcelletransplantasjon - antineoplastiske midler - i kombinasjon med annen kjemoterapi legemidler:med eller uten hele kroppen bestråling (tbi), som condition behandling før allogen eller autologous haematopoietic stamfar cellen transplantasjon (hpct) i haematological sykdommer i voksen og paediatric pasienter, når høy dose kjemoterapi med hpct støtte er aktuelle for behandling av solide svulster hos voksne og paediatric pasienter. det er foreslått at tepadina må forskrives av leger med erfaring i bad behandling før haematopoietic stamfar cellen transplantasjon.

Thiotepa Riemser ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

thiotepa riemser

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiske midler - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.